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3. Progress Report. (See Instructions) 
1. None 
2. The project has just been started. Two graduate research associates, Brian McRae 
and Mario Castillo, began work on the project during the year. Charles Vencill, 
a graduate research associate, will begin this summer. 
3. Progress Report 
Objectives. The objectives of the present research are to 1) design and synthe-
size specific substrates for assaying blood proteases, 2) determine the kinetic 
parameters for reaction of various blood proteases with the substrates using 
purified enzymes, 3) study the nature of the extended substrate binding site 
in plasma proteases, and 4) synthesize and study the reactivity of peptides 
corresponding to plasma protease cleavage sites. 
The program of study has just been started and goals for the current year 
were to investigate synthetic methods for thiol ester substrates of plasma pro-
teases (objective 1) and to synthesize peptides corresponding to plasma pro-
tease cleavage sites (objective 4). 
Peptides Corresponding to Plasma Protease Cleavage Sites. Serine proteases such 
as Factors IXa' XI and XIIa probably recognize both a specific amino acid se-
quence and a specific conformation in their natural substrates. As an initial 
working hypothesis, I have assumed that recognition of the sequence is the most 
important and that synthetic substrates with the appropriate sequence should be 
fairly specific for individual enzymes. Thus an appropriate Factor IX a substrate 
would be something with the sequence RCO-Gln-Val-Val-Arg*Ile-Val-Gly-NH 2 
(*indi-
cates the cleavage site in Factor X, Factor IX 'ssubstrate). Intially we have 
decided to concentrate all of our effort on Fac
a
tor IXa , XIa and XIIa substrates. 
Very little research with synthetic substrates has been reported thus far with 
these enzymes and thus we may be able to gain new insights about the active 
sites of these enzymes. Some of the peptides which we are in the process of 
synthesizing are listed below: 
Factor IXa substrate (sequence of Factor X cleavage site) 
Abz-Gln-Val-Val-Arg*Ile-Val-Gly-Nba 
Factor XI a substrates (sequence of Factor IX cleavage sites) 
Abz-Glu-Phe-Ser-Arg*Val-Val-Gly-Nba 
Abz-Lys-Phe-Ser-Arg*Val-Val-Gly-Nba 
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Factor XIIa substrate (P1-P3 - corresponds to Factor XI cleavage site) 
Abz-Ala-Ala-Ala-Arg*ile-Val-Gly-Nba 
In each case the N-terminus of the peptide is blocked with a 2-aminoben-
zoyl (Abz) group and the C-terminus is protected as the 4-nitrobenzyl amide 
(Nba). The rate of enzymatic hydrolysis for each of these substrates will be 
monitored using fluorometric techniques. The aminobenzoyl group is fluorescent 
and the nitrobenzyl group is a quenching group. Upon hydrolysis, the quenching 
group is separated from the fluorescent group such that the latter freely fluo-
resces after excitation at an appropriate wavelength. The rate of increase in 
fluorescence corresponds to the rate of hydrolysis of the peptide. 
The synthesis of three shorter peptides (Abz-Val-Val-Arg*I1e-Fiat-Gly-Nba, 
Abz-Val-Val-Arg*Ile-Val-Nba, Abz-Val-Arg*Ile-Val-Gly-Nba) has already been 
completed. The reactivity of the three peptides toward Factor IXa , Xa , and 
XIa were measured by Dr. K. Kurachi and Dr. E. Davie at the U. of Washington, 
Although they were effectively hydrolyzed by trypsin, they were poor sub-
strates for Factors IXa , Xa and XIa . These findings inspired the synthesis of 
peptides with an extended N-terminus such as Abz-Glu-Val-Val-Arg*Ile-Val-Gly-
Nba which is in progress. We believe P4-P 3 ' interactions may critical for 
substrate recognition by the various clotting enzymes. 
Specific Substrates-Thiol Esters. Peptide thiol esters such as Ac-Arg-SIle-NHR 
(SIle = -SCH2(C4H9)C0-) should be useful in sensitive assays for the serine 
proteases involved in clotting. Hydrolysis at the Arg-Sile bond would yield a 







CHCH CH 2 3 
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As the peptide is hydrolyzed, the Absorbance at 410 nm increases as the released 
thiol reacts with Ellman-s reagent. Since thiol esters are good substrates for 
serine proteases and Ellman's reagent can detect low levels of thiol, the pro-
posed substrates should be quite sensitive. Recently we have synthesized the 





cyte elastase hydrolyzes this compound very effectively and the-substrate can be 
used to assay elastase concentrations as low as 5 picomolar. 
One significant advantage of thiol ester substrates is their use of P' re-
sides. Thus it is possible to design a substrate for an enzyme where only the 
new N-terminal sequence released on cleavage of its substrate is known. Thus a 
substrate such as Ac-Arg-SIle-Val-Gly-Gly-NH 2 could be used to study or detect 
enzymes that activate Factor VII. It should be noted that the Arg-SIle bond 
in the above substrate differs from the Arg-Ile bond in the natural substrate 
simply by replacement of the NH of the peptide bond with a sulfuratom. 
Our first synthetic goal was Ac-Arg-SIle-Val-Gly-NH 2 . The synthesis of 




ever we have thus far been unable to couple this thiol with a number of blocked 
arginine derivatives. We then decided to work out the synthetic methods with a 
series of simplier arginine thiol esters (1, 2 and 3). 
CH3 	 CH3 	 CH3, ,CH3 
,CH3 	 ,CH2CH3 	 CH 
CH 	 CH 	 CH2 
Ac-Arg-S-6-1 2 Ac-Arg-S-CH2 Ac-Arg-S-CH2 
1 
	
2 	 3 
The structures incorporate respectively the side chains of a P 1 ' valine, isoleu-
cine and leucine residue. The activation site of the zymogens of all known se-
rine proteases involves cleavage of a Arg-Val, Arg--Ile or Arg-Leu bond. These 
three substrate will thus allow us to study the P1 - specificially of activating 
serine proteases such as Factor IX a , XIa and XIIa . 
We have completed the synthesis of 1 and are currently working on the synthesis of 
2 and 3. Purfication of reaction products is our major difficulty. We expect 
high pressure liquid chromatography to be extremely useful in this regard and 
are currently constructing a system to be used in the purification of arginine 
peptides. Once we have worked out the methods for the synthesis and purifica-
tion of 1, 2 and 3, we will return to the synthesis of larger thiol esters such as 
Ac-Arg-SIle-Val-Gly-Gly-NH 2 . 
The kinetics of reaction of 1 with trypsin (Kcat/Km = 2.9 X 10-A M
-1 
 s-1 ) have 
been measured at pH 7.5, but no kinetic work has been yet done with any of the 
clotting factors. 
Research Goals for the Coming Year. 
1) Complete the synthesis of several fluorescent peptide substrates and measure 
the kinetics of their reaction with various blood clotting serine proteases. 
2) Develop methods for the synthesis and purification of arginine thiol esters. 
Study the reaction of simple derivatives with various clotting factors and 
begin the synthesis of longer arginine thiol esters. 
Significance. The plasma proteases that will be investigated in the proposed 
research are involved in a number of important physiological processes such as 
blood coagulation, fibrinolysis and kinin formation. A humber of clinical as-
says are based on the determination of the activity of various plasma proteases 
mostly using clotting assays. The synthetic substrates which will be developed 
in this research should be quite sensitive and specific and should allow assays 
to be developed for plasma component which are impossible currently due to the 
complex nature of clotting assays. Since they are spectrophotometrically or 
spectrofluorometrically based, they would be usable in most clinical labs, even 
those without extensive instrumentation. 
The proposed research would lead to a better understanding of the nature of 
the active site structures of various plasma proteases and how they are affected 
by various plasma modulators such a s phospholipids. This should give us a bet-
ter understanding of various diseases such as coagulation disorders and tumors 
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which release the plasminogen activator. This in turn could lead to new ave-
nues of therapy where various specific activators or inhibitors are used to 
control the activity of certain plasma proteases. 
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The objective of - the proposed research is to prepare a series of sensitive and 
specific substrates for assaying blood proteies such as Factors Vil a, IXa, Xa , XIa , XIIA 
piasula„—taroabin, kallikrein and the plaszinogen activator. These proteins are the basil 
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research may lead to new methods for disease detection or to new mechanisms for the 
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